Amplia Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INNMF research report →
Price Chart
About the company
Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors. The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases. Its drug development pipeline includes AMP945, a FAK inhibitor that has successfully completed Phase I clinical trials and is being explored for its efficacy in treating pancreatic cancer, idiopathic pulmonary fibrosis, and a broader spectrum of cancerous and fibrotic conditions.
- CEO
- Christopher J. Burns
- IPO
- 2021
- Employees
- 1
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on INNMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $35.93M
- P/E
- -6.29
- PEG
- -0.26
- P/S
- 0.00
- P/B
- 1.36
- EV/EBITDA
- -2.05
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -18.71%
- ROIC
- -20.41%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-92,314-102.6%
- Op Income
- $-13,205,020
- Net Income
- $-7,721,716-17.5%
- EPS
- $-0.02+23.4%
- OCF Growth
- -27.1%
- FCF Growth
- -27.5%
- 52W High
- $0.27
- 52W Low
- $0.05
- 50D MA
- $0.09
- 200D MA
- $0.10
- Beta
- -0.42
- RSI (14)
- 30
- Avg Volume
- 15.60K
No earnings-call transcripts are available for INNMF yet.
- Free Float
- 93.3%
- Shares Outstanding
- 513.31M
- Float Shares
- 479.04M
Our INNMF coverage
Recent articles, reports, and earnings notes.
No research on INNMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INNMF report →Amplia Therapeutics partners with Lilly on lung cancer combination trial
proactiveinvestors.com · Aug 4
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
globenewswire.com · Aug 4
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
globenewswire.com · Jul 31
Amplia Announces Publication of New FAK Inhibitor Patent Application
globenewswire.com · Jul 9
Amplia Announces Appointment of Brett Carter to Board
globenewswire.com · Jul 7
Amplia Announces Changes to Board's Leadership Roles
globenewswire.com · Jul 6
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
globenewswire.com · Jun 22
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
globenewswire.com · May 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.